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ABSTRACT 
Many drugs are available in the market for several diseases, disorder or even for a condition, but it is difficult to select a suitable carrier to attain 
maximum bioavailability and potential for a potent drug. Attaining a controlled and sustained release of a drug is purely focused on the selection of 
a carrier (natural, synthetic and hybrid) like nanosomes. Nanosomes have become a prominent tool in the field of pharmacy. Nanosomes are small 
uniform structures which deliver the drug to the specific targeted site, which mainly depends upon the presence of ligands, shape, size and surface 
chemistry. Nanosomes are available in various types which include Niosomes, Liposomes, Electrosomes, Aquasomes, Transfersomes, Phytosomes, 
Enzymosomes, Ethosomes, Invasome and Sphingosomes. In general, all these nanosomes are quite similar in nature with minute differences in their 
vesicular characteristics and composition. This review traces various ‘Somes’ composition and their role in the formulation, applications, 
advantages, disadvantages, common formulation procedures and evaluation parameters.  
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INTRODUCTION 
Though different drugs are available in the market for a spectrum of 
disease, disorder or even for a condition, their drug delivery system 
plays a key role in it, starting from avoiding unnecessary side effect 
still their cost effectiveness. Formulating a rational formulation is a 
challenging process for a pharmacist. In which, it is difficult to select 
a suitable carrier to attain maximum bioavailability and potential for 
a potent drug. 
In 1909, Paul enrich developed and initiated the Drug targeting era. 
In drug targeting the active medicament or the therapeutic agent of a 
drug reaches the targeted site without getting metabolized through 
escaping from the first pass metabolism, with improved 
bioavailability and reduced unintended side effects. 
Attaining a controlled and sustained release of a drug is purely 
focused on the selection of a carrier like nanosomes for a drug 
represented in fig. 1. Nanosomes are small uniform structures which 
delivers the drug to the specific targeted site, which mainly depends 
upon the presence of ligands, shape, size and surface chemistry. 
Based on different aspects like therapeutic uses, lipoidal and 
nonlipoidal barriers they are of different types which includes 
Niosomes, Liposomes, Electrosomes, Aquasomes, Transfersomes, 
Phytosomes, Enzymosomes, Ethosomes, Invasome and 
Sphingosomes [1-10].  
The drugs can be encapsulated into the different types of vesicular 
structures using various types of mechanisms and formulation methods. 
The various ‘Somes’ composition and their role in the formulation, 
applications, advantages, disadvantages, common formulation 
procedures and evaluation parameters were discussed below. 
Articles are reviewed from 1975 to 2020 and keywords used for this 
review are the preparation, evaluation, and application of niosomes, 
liposomes, electrosomes, aquasomes, transfersomes, phytosomes, 
enzymosomes, ethosomes, invasomes, sphingosomes. 
 
 
Fig. 1: Structures of various somes [21, 28, 51, 72, 74] 
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Fig. 2: (A) Structure of Noisome; (B) Types of niosomes 
 
 
Fig. 3: (A) Structure of liposome; (B) Liposomes types based on size [21, 28, 38, 39, 51] 
 
Niosomes 
The main perspective of developing niosomes to overcome the 
problems related to sterilization, large scale production and 
stability. Niosomes are thermodynamically vesicles, which are 
similar to liposomes and microscopic in size ranges on a nanometric 
scale ideally suitable for transdermal delivery. It is composed of 
hydrated compounds of cholesterol, charge inducing substances and 
nonionic surfactants like mono alkyl and dialkyl polyoxy ethylene 
ether used mainly carriers of lipophilic and amphiphilic drugs. The 
niosomal structure is shown in fig. 2(A). It delivers the medicament 
in target site with less risk of side effects and toxicity. Surfactant 
form lipid bilayer when it interacts with the aqueous media. Based 
on size of niosomes it is classify into 3 types  
1. Small Unilamellar Vesicles SUV (0.05-0.5μm)  
2. Multi Lamellar Vesicles MLV (0.05μm)  
3. Large Unilamellar Vesicles LUV (0.10μm) as shown in fig. 2(B) [2, 3] 
Liposomes 
Liposomes are concentric bilayer vesicles and microscopic in nature, 
in addition to it, they are capable of loading potent drug along with 
phospholipids to aim on drug targeting. In Liposomes phospholipids 
are dispersed in the aqueous solution they rapidly form multi-
lamellar concentric bilayer vesicles which are about 0.05-5.0μm 
diameter as pictured in fig. 3(A). It is also called as micro particulate 
or colloidal barrier [4]. 
Based on surface charge, these are of 3 types. 
1. Liposomes with positively charged 
2. Liposomes with negatively charged 
3. Liposomes with neutral charged 
Liposomal corneal penetration: Positively liposomes ˃ negatively 
liposomes ˃ neutral liposome [4]. 
Based on the vesicle size liposomes are categorized into 
1. Multi Lamellar Vesicles (˃0.1μm)  
2. Small Lamellar Vesicles (0.1μm) 
3. Large Lamellar Vesicles (˂0.1μm) represented in fig. 3(B) [4]. 
Structure and components of various types of liposomes are shown 
in fig. 4. 
Aquasomes 
It is a self assembly of triple layered particles with large surface 
area. It is also called as “Bodies of water” which acts as protein and 
peptide carrier. These are spherical in shape with a diameter of 60-
300 nm [5]. It has a property of maintaining a conformational 
reliability with a high degree of exposure to the surface. It protects 
the fragile biological molecule. Aquasomes uphold molecular 
confirmation and optimal pharmacological action. It delivers the 
drug at a specific target site with molecular shielding of contents in a 
sustained release mechanism. It consists of ceramic core which is 
surrounded by the polyhydroxy oligomers and the active drug is 
entrapped in the coating by absorption through ionic and non 
covalent interaction represented in fig. 5(A) [5]. 
Transfersomes (Elastic liposomes) 
These are used in targeted controlled drug delivery system which is 
ultra flexible and has deformable vesicles less than 300 nm [6]. It can 
penetrate to a pore to the deeper epidermis layers (i.e. Stratum 
corneum to stratum bacile) and then enters the systemic circulation 
for the potential drug delivery. It is composed of buffer solution, dye, 
small amount of alcohol, surfactant and soya phosphotidyl choline. 
Surfactant acts as edge activator and increases the permeability 
across the skin represented in fig. 5(B) [6]. 
Invasomes 
It is a liposomal vesicle that is neutrally charged which are capable 
of deliver both the hydrophilic and lipophilic drugs over deeper 
layers of epidermis and exhibits its action [7]. They are Great 
potential carriers for the transdermal skin delivery. It is composed 
of small amounts of ethanol, terpene or terpene mixtures (1-5%) 
and Phosphotidyl choline as depicted in fig. 5(C) with increased 
concentration of terpene in the composition the vesicle size and 
membrane elasticity increases [8, 24]. 
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Fig. 4: Structure and components of various types of liposomes [21, 28, 38, 39, 51] 
 
Phytosomes 
Phytosomes are a type of herbosomes, which are mainly composed of 
Phytoconstituents (neutraceuticals such as flavonoids and terpenoids) 
which ranges from 500 nm-100μm as represented fig. 5(D). It is a 
complex of lipid molecules that enhances the bio availability, the 
solubility of the drug and absorption of water soluble 
Phytoconstituents. It is composed of aprotic solvent, phytoconstituents 
and phosphotidyl choline. It acts as a potential carrier for anti skin 
ageing agent and non pathogenic disorders. Phytosomal formulation 
improves antioxidant property and protects the cardiovascular system 
from oxygen residues by preventing ischemic heart disease [9]. 
 
 
Fig. 5: (A) Structure of aquasome [53, 46]; (B) Structure of Transferosome and it comparison with Liposome [51, 60]; (C) Structure of 
Invasome and it comparison with Liposome [8, 24]; (D)Structure of Phytosomes [9, 22, 26]; (E) Structure of Enzymosomes [11]; (F) 
Structure of sphingosomes [12, 29] 
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Enzymosomes 
Enzymosomes are the enzymes which are encapsulated over the 
liposomal vesicles and the attachment is mediated by covalent 
bond/coupled formation as shown in fig. 5(E). These types of 
vesicles are used for the treatment of targeted drug delivery in 
tumor cells. This formulation can increase the antitumor activity of 
drugs. The enzymes which are encapsulated in the liposomal 
vesicles are β-lactanase, β-glucosidase, carboxy peptidase and 
alkaline phosphatise. These enzymes pave a way for the following 
1. Gene delivery to the tumor cells through the catalysis of the 
enzymes.  
2. Pharmacological action at the specific site. 
3. Activation of prodrug. [10, 11] 
Sphingosomes 
Sphingosomes are bilayer concentric vesicles. It was first discovered 
by University of British Columbia and it was developed by Inex 
Pharmaceutical Corporation [12]. It is composed of stearyl amine, 
cholesterol and sphingolipid. The structure of vesicles in the 
Sphingosomes is similar in liposomal structure as represented in fig. 
5(F) but it differs in the composition of phospholipids called as 
sphingolipid. It maintains drug retention properties and provides 
stability towards acid hydrolysis. It is administered through the 
route of intravenous, intramuscular, inhalation, oral and 
transdermal. Used as carriers for ionotrops, psychotropic’s, nucleic 
acids, lipophilic cations [12]. 
  
 
Fig. 6: Structure of ethosomes [51, 58, 60] 
 
Ethosomes 
Lipoidal vesicles with high concentration of ethanol called as 
Ethosomes. Ethosomes are also known as ethanolic liposomes. The 
fig. 6 it is a soft and a novel vesicular carriers for the transdermal 
drug delivery over deeper layers of skin as a controlled release 
mechanism. It is composed of water, cholesterol, dye, polyglycol, 
ethanol (20-50%), vehicle, and phospholipids. High concentration 
of ethanol enhances the ability of drug permeation through skin 
[13]. 
Electrosomes 
Electrosomes are novel surface display system. It is a 
transmembrane protein. It generates and propagates electrical 
signals which allow sensing the surroundings. Interaction between a 
cascade of redox enzymes and scaffolding for multiple releases by 
oxidation of fuel. It is composed of dockerin containing enzyme 
which attaches to the cohesive sites of scaffolding to assemble the 
ethanol oxidation cascade as hybrid anode and dockerin containing 
oxygen reducing enzyme attached to multiple copies to cohesion 
bearing scaffolding as hybrid cathode [14] 
 
Table 1: Types of excipients and their role in somes drug delivery system 
S. No. Types Composition  Role Reference 
1. Niosomes 
 
a. Nonionic surfactants: Spans and 
Tweens, Poly hydroxyl groups and Cetyl 
alcohol. 
 1-10 mmol (1-2.5%). 
 HLB value 4-8. 
 Entrapment efficiency. 
 Drug encapsulation. 
2, 3 
b. Phospholipids: Dicetyl phosphate, 
Stearyl amine. 
 Helps in the formation of vesicles interact with aqueous 
media. 
c. Cholesterol  Provide proper shape and rigidity for the niosome. 
 Stabilizes permeability bilayer fluidity and stability. 
2. Liposomes a. Cholesterol  Changes in permeability. 
 Effect of particle size. 
4 
b. Surfactants: Phosphotidyl serine, 
Phosphotidyl choline. 
 May change to different phases based upon transition 
temperatures. 
c. Cholesterol: Sterols.  Decrease the encapsulated drug leakage. 
 Plays major role in bilayer fluidity. 
 Acts as fluidity buffer. 
3. Invasomes 
 
a. Phosphotidyl choline  Increasing flexibility of vesicles. 
 Edge activator. 
7, 8, 19 
b. Terpene  Increasing lipid bilayers of skin. 
 Increases diffusion of drugs by extracting lipid from SC. 
Brito et al. 
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 Acts as penetration enhancers. 
c. Ethanol  Helps in increasing fluidity. 
 Ability to squeeze through the small pores of skin. 
 Increases stability of vesicles to penetrate over the skin. 
4. Phytosomes 
 
a. Phospholipids: Phosphatidyl choline 
(Ionositol, Serine, Ethanolamine) 
 Prevents the drug from water triggered degradation. 
 Carrier for both water and fat miscible nutrients. 
 Natural digestive aid. 
9 
b. Phyto constituents: Terpenoids, 
Flavanoids 
 Exhibits Therapeutic action 
c. Aprotic solvents: Ethyl acetate, 
Methylene chloride, acetone, Dioxane 
 Provides solubility. 
5. Enzymosomes a. Enzyme: Alkaline phosphatise, 
Carboxy peptidase, β-glucosidase, β-
lactanase 
 Prodrug activation. 
 Covalent attachment with liposomal vesicle for 
therapeutic action. 
10, 11 
b. Liposomal vesicle: Cholesterol, 
Surfactant and Phospholipids 




a. Spingolipid: Ceramide, Sphingosine, 
Sphingomyelin  
 Maintenance of drug retention properties. 
 Increases stability to acid hydrolysis. 
12 
b. Cholesterol  Reduces electrostatic and hydrogen bonding in 
interaction of vesicles. 
c. Stearyl amine  Increases the stability of sphingolipid. 
7. Ethosomes 
 
a. Phospholipid: Dipalmityl phosphtidyl 
choline, Phosphatidic acid, Phosphotidyl 
choline  
 Elasticity to vesicles. 
 Formation of vesicles. 
 
13 
b. Cholesterol  Stability to vesicles. 
c. Alcohol: Isopropyl alcohol, Ethanol  Creates disturbance of skin lipid bilayer organization. 
 Penetration enhancer. 
d. Dye: Rhodamine red, Rhodamine-
123, Isothiocynate, Fluorescence  
 Characterization study. 
e. Polyglycol: Transcutol RTM, 
Propylene glycol 
 Enhance penetration. 
f. Vehicle: Carbopol D94  For gel former. 
8. Aquasomes 
 
a. Solid core: Ceramic, diamond, 
Hydroxylapatite and Calcium 
phosphate. 
 Specific targeting. 
 Molecular confirmation. 
 Maintains structural stability. 
15, 18 
b. Coating material: Trehalose, 
cellobiose, Polyhydroxy oligomers, 
carbohydrates. 
 Protects the drug from denaturing effects of pH and 
temperature. 
 Acts as dehydro protectant. 
c. Drug  Gives therapeutic action by, non covalent bonds, entropic 
forces, ionic and vanderwaal forces. 
9. Transfersomes 
 
a. Surfactant: Dipotassium 
glycyrrhizinide, Deoxycholate, Span80, 
Tween 80, Sodium cholate. 
 Increases vesicle deformability, permeability, fluidity. 
 Acts as edge activator. 
16, 17 
b. Phospholipid: Soya phosphotidyl 
choline. 
 Helps in formation of vesicle complexes. 
c. Alcohol: Methanol, Ethanol.  Solvent for solubilisation of drug. 
d. Buffer: Saline phosphate buffer 
(pH6.4) 
 Hydrating medium. 
e. Dye: Nil red and Rhodamine 123.  For study of confocal scanning laser microscopy. 
10. Electrosomes 
14 
a. Hybrid anode: Dockerin containing 
enzymes of formaldehyde 
dehydrogenase, Aldehyde 
dehydrogenase. 
 Assemble ethanol oxidation cascade. 14 
b. Hybrid cathode: Dockerin containing 
reducing oxygen enzyme of copper 
oxidase. 
 Attach to multiple copies to the cohesion bearing 
scaffolding protein. 
 
Table 2: Formulation methods for preparation of various somes drug delivery system 
S. No. Formulation Types Procedure Reference 
1. Hot method 
 
Ethosomes Phospholipids in water and propylene glycol in ethanol were added and heated 
separately upto 40 °C and mixed well. Finally the therapeutic agent was added. 
13 
2. Cold method 
 
Ethosomes Excipients were added to the ethanol and dissolved by vigorous shaking and 
heated. At 40 °C propylene glycol was added. Then water was added to it for 5 min 
with continuous stirring and the particle size is reduced by sonication and 
extrusion method. This final formulation was stored in refrigerator. 
13 




drug loading  
Aquasomes Core preparation: Ceramic core was fabricated by colloidal precipitation and it is 
sonicated under ultrasonic bath at 4 °c for 2hr and a precipitate is formed. 
Precipitated cores are then centrifuged, washed to remove any traces of NaCl 
formed during the process. Precipitated cores are resuspended in distilled water 
and then filtered in a fine membrane. 
2Na2HPO4+3CaCl2+H2O→ Ca3(PO4)2+4NaCl+2H2+Cl2+(O) 
Coating: Cores are dispersed in aqueous solution of coating material and kept for 
18 
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sonication and lyophilization for the irreversible adsorption of coating material to 
the core. 
Drug loading: Finally, the drug was loaded into the coating material through 
adsorption by dispersing in the suitable buffer solution containing drug at low 
temperature.  






Suspension is taken into the glass vial and subjected to sonication for 5-10 min at 
60 °C with the help of sonic energy suspension yields small unilamellar vesicles of 
15-50 nm 
(small volumes-probe type sonicator; large volumes; bath type sonicator)  
20, 21 









Surfactants and cholesterol were solubilized in a round bottomed flask containing 
organic solvents (chloroform, diethyl ether) and subjected to rotary evaporator 
for the evaporation of volatile solvent. A thin film is shaped inside the glass walls 
of the flask. Afterwards the phosphate saline buffer (PBS) was added to it to 
rehydrate the thin film and allowed to sonication and this lead to the creation of 
Multilamellar vesicles (MLV). In Enzymosomes, enzymes which are already 
dissolved in phosphate buffer (pH-5.6) were dispersed in liposomal vesicle 
suspension for encapsulating enzyme over the vesicles. 




The hydrated thin film suspension was allowed for sonication for the desired size 
and it is homogenized through the extrusion polycarbonate membrane. Volatile 
solvents were added to dissolve the contents and then subjected to rotary 
evaporator for the evaporation of volatile solvents and buffer solution (pH6.5) 
was added to the lipid film for 1hr at 60 rpm. After 2 h vesicles get swollen at 
room temperature. Large uniamellar vesicles (LUV) are obtained by this method. 
(subjected to sonication SUV are obtained with probe type at 40 °c for 30 min, 
bath type at 500 °c for 30 min). 
11, 16, 20, 
21, 22 
6. Microfluidizer Niosomes 
Liposomes 
Sphingosomes 
Drug, surfactants and excipients were pumped into the interaction chamber at a 
pressure of 100 ml/min; 10,000psi and then passed to the cooling loop for 
removal of heat during the process and allowed to recirculation until the 





Phytosomes Drug and phospholipids were refluxed with 20 ml of acetone in a 100 ml round 
bottomed flask at 50-60 °C for 2hr, then concentrate the suspension to 5-10 ml. A 
phytosomal precipitate formed it is collected, filtered and dried. 
22 







Surfactant and cholesterol are dissolved in the organic solvents and aqueous 
buffer and was allowed for sonication for the formation of o/w emulsion and 
allowed for evaporation of organic solvents by rotary evaporator. This Leads to 
the formation of viscous gel. To this phosphate buffer was added for hydration and 









The ethanol/ether solution was injected slowly using a syringe in the aqueous 
medium containing drug and formulation excipients at 60 °C. It was allowed for 
heating or subjected to vacuum for the removal of ethanol/ether solution and this 
leads to the formation of small unilamellar vesicles (SUV) (50-1000 nm) 
(14 gauge needle for niosomes and 22 gauge needle for liposomes). 
27-30 







Drug and phospholipids were dissolved in organic solvents and allowed to freeze 
and dried. Then saline water was added to the formation of vesicles. 
27-30 
 
Table 3: Advantages and disadvantages of types of somes 





 Compared to iontophoresis and 
phonophoresis it is a simple transdermal method 
of drug delivery. 
 Formulated in semisolid (gel) for patient 
compliance. 
 Formulation, contains non-toxic raw material. 
 Drug delivery by non-invasive technique. 
 Reaction of phospholipids causes 
oxidation/hydrolysis leads to instability of 
invasomal formulation. 
 The encapsulated drug leads to leakage 
or fusion. 







 Increased pharmacological action and 
prodrug activation 
 Completely biodegradable in nature. 
 Non-toxic nature. 
 Increased stability and encapsulation. 
 More than 1 enzyme moiety is formulated to 
achieve targeted drug delivery. 
 
 The drug molecule may cause leakage or 
fusion while encapsulating. 
 Chances of low solubility, reduction in 
half life leads to reduced bio availability. 
 The phospholipids, which are present in 
liposomal vesicles may cause hydrolysis 
and oxidation reactions thus it effect the 
stability  
 Expensive production cost for 






 Passive drug targeting in tumor therapy. 
 Better drug retention properties. 
 Increased circulation time for 
pharmacokinetic effect. 
 Less risk of toxicity in encapsulating agents. 
 Great potential towards stability in 
 Less entrapment efficacy. 
 Expensive production cost. 
 
12 
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 When compared to iontophoresis and 
phonophoresis ethosomal formulation is a simple 
method of drug delivery. 
 High patient compliance in semisolid 
formulation. 
 Possible delivery of large molecules such as 
proteins and peptides. 
 Ethosomal formulations are widely used in 
pharmaceutical, veterinary and cosmetic fields. 
 Non toxic in nature. 
 Less solubility of the drug in lipophilic 
and aqueous environments to reach the 
dermal micro circulation and then to 
systemic circulation. 
 Slow, sustained drug delivery in bolus 
type drug input. Excipients and enhancers 
may cause skin irritation and dermatitis. 
 Product will be loss when transfer from 
organic to aqueous media. 






 Osmotically stable and active. 
 Improves oral bio availability of soluble drugs. 
 Low doses can achieve target drug delivery. 
 Enhances more stability and economy. 
 More potential and less side effects when 
compared to other drugs. 
 Leakage of entrapped drug takes place. 
 Hydrolysis may take place in entrapping 
drug. 
 Insufficient drug loading. 
 Aggregation of suspension. 






 Formulated in the delivery of both systemic 
and topical application. 
 Protection of encapsulated drug from 
metabolic degradation. 
 Act as carrier in both low and high molecular 
weight drugs. 
 Bio compatible and biodegradable in nature. 
 Great penetration of intact vesicles due to 
high deformability. 
 Absence of purity in natural 
phospholipids. 
 These are chemically unstable due to the 
predisposition of oxidative degradation. 




7.  Aquasomes 
 
 Great potential in solubility, stability, rapid 
degradation of drug molecule  
 Improvement of therapeutic efficacy of active 
agent and less side effects. 
 controlled and target drug delivery in various 
routes of administration. 
 Used in the various imaging tests. 
 Care should be taken in production of 
carriers 
 Dose dumping is carried out by carriers. 
 Expensive. 




8.  Liposomes 
 
 Increased accumulation in the target site. 
 Completely biodegradable. 
 Carriers for controlled and sustained release 
drugs. 
 Less risk of toxicity. 
 Simple and easy attachment of targeted 
ligands. 
 Problems will arise in repeated i. v 
administration. 
 Difficulty arises in stability due to short 
life.  
 Reactivity of phospholipids may occur. 
 Expensive. 






 Enhances absorption of lipid insoluble polar 
drugs of oral and topical. Nutritional benefits. 
 Enhanced permeation of phytoconstituents 
through the skin. 
 Hepatoprotective synergistic effect due to 
phosphotidyl choline. 
 High entrapment efficiency. 
 Phytoconstituents are rapidly eliminated 
from phytosomes. 
 Phytosomes are sensitive the pH of 
phospholipids. 
 Leaching of phytoconstituents leads to 




Table 4: Evaluation parameters of various somes 












Microscopy Scanning electron microscopy (SEM), 
Transmission electron microscopy 
(TEM). 
35-45 
Liposomes Freeze fracture 
technique 
Freeze fracture electron microscopy, 
Freeze-etch electron microscopy. 




Unimodel method of 
data processing 







rate, dynamic light 
scattering 
Optical microscopy, Nanosizer,  












Photon co relation 
spectroscopy 
Malvern zeta sizer,  
Zeta sizer Beckmann coulter 
52-56 
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4.  Drug entrapment efficiency 

















Mini column centrifugation. 
5. 
 
Invitro drug release 
 








Incubation Cellophone membrane, 























Florescence marker Confocal scanning laser 
microscopy(CSLM) 
16 
9. Turbidity  Transfersomes Observation Nephelometer 16 
 
Table 5: Applications of various somes in drug delivery system 





 Used in formulating anti-inflammatory, breast cancer and metastases drugs. 
 Gene delivery to the tumor cells. 






 Used for Treatment of thromboembolic disease in rabbits. 
 Used in anti microbial drugs, anti fungal drugs and viral therapy. 
 Enzymes such as Sterptokinase urokinase esterase are prepared in spingosomal vesicles. 
 Used for Formulating the drugs which are used for tumor therapy. 






 Antiviral drugs such as Acyclovir is formulated using ethosomes is used topically to treat Herpes 
Labialis. 
 Cannabidol is formulated using ethosomes for the treatment of rheumatic diseases. 
 Ethosomes enhances greater permeation of ferulic acid through the stratum corneum epidermal 
barrier. 
 Hormones are formulated using ethosomes and administered transdermally to protect from the 
first pass effect in oral formulation. 
 Ethosomes are formulated in oral drug delivery of biogenic molecules For therapeutic efficiency 
and permeation. 
13 
4.  Electrosomes 
 
 Ear targeting  
 Muscle targeting. 
 Nervous system targeting. 
 For brain targeting formulations. 






 Multilayered core (5 layers) is used as targeted intracellular gene therapy. 
 Used as Immuno adjuvant for proteinaceous antigens. 
 Haemoglobin is formulated in hydroxyl apatite (core) coated with trehalose treated as an 
oxygen carrier.  
 Formulation of chitosan coated Serratiopeptidase in oral drug delivery. 
 Pyridoxal-5-phosphate coated insulin shows good response in parenteral delivery. 
18 
6.  Invasomes 
 
 Formulation of curcumin using invasomes increases the solubility and bio availability of the 
drug. 
 To control tyrosinase activity for hyper pigmentation disorders phenylethyl resorcinol loaded 
invasomes are used. 






 Localized and encapsulated drugs with niosomes are used to treat tumours. 
 Potent target drug delivery in Reticulo endothelial system (RES). 
 Used in Formulation of anticancer drugs, Tuberculosis drugs, Leishmania, inflammatory and 
hormonal drugs. 
 Used in the encapsulation of Colchines, Estradiol, Tretion, Dithranol. 






 Induces Great transdermal immunization in transcutaneous hepatitis-B vaccines. 
 Shows good immune response in human serum albumin/gap junction. 
 Targeted delivery of insulin to systemic circulation, which is equivalent to subcutaneous 
77-79 
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injection. 
 Used as carriers for steroids, NSAIDS, anticancer drugs, local anaesthetics. 
 Formulated in vaccines, steroids, protein and peptide delivery across the skin. 





 Shows greater potential in cosmetics as anti skin ageing agent and cosmetics that treats non 
pathogenic skin conditions. 
 Therapeutically used in the formulation of cardiovascular, anti inflammatory, anticancer drugs. 
 Used in the transdermal application of inflammation, toxicities, weight loss, cancers, chronic and 
acute degenerative disorders. 






 Monoclonal antibody directed liposome is used as vectors For genetic transfaction. 
 In ocular delivery, approved drug Verteporfin (liposome) is used. 
 Used in small cytotoxic molecules in tumour therapy. 
 Carriers for antineoplastic drugs, anti microbial drugs, chelating agents, steroids, vaccines, 
genetic materials. 
 Role in formulation of potent drug for therapeutic action. 
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Table 6: Patents of various somes (2018-20) 
S. No. Type of 
somes 
Title  Author Publication no./ 





Preparation for Mortellaro’s disease 
treatment 
Belyakova Natalya, Aleksandrovna, Bodrova 
yulya yurevna, Dorofeev Andrej fedorovich, 
Kovalenko anatoliz, Mikhajlovich, Kurbanov 
rusllan zamirovich,Yavnikov nazar 




Preparing method for positively electrified 
charged niosome, and charged niosome 




Topical composition comprising plant 
extracts 
Pacchetti Barbara AU2017243956A1/ 
2018 




Liposomes comprising sphingomyelin Halbherr Stefan W0201922220A1/ 
2019 
Cataplasm mask containing flexible nano 
liposomes 




3. Aquasomes Gel formulation for treating diabetic foot 
ulcer 
Uma Shankar marakanam, Srinivasan US2020188314A1/ 
2020 
Topical compositions for stimulating hair 
growth 
Brichtla lars W02019236596A1/ 
2019 
Acoustic field coupling with micro-devices Freitas JR Roberta, Hogg tad US10024950B1/ 
2018 
4. Phytosomes Composition for prevention or treatment of 
skin inflammation comprising centella 
asiatica phytosome and Mori Radicis cortex 
extract 
Jang jun sung, Kim has sung, Myung pyung 
kelin, Park ju ho, Park mork soon 
KR102073009B1/ 
2020 
Method of producing nanoscale phytosome 
system 
Kezimana parfe, Marakhova anna igrevna, 
Shvitko boris semenovich, Smagulova dilda, 
Stanshevskij yaroslav mikhalovich 
RU2680809C2/ 
2019 
A carrier for pulverization of oils, fatty acids 
and hydrophobic substances 
Beran milos, Drahorad Josef, Hromadka 
Robert, Vltasvsky ondrej 
CZ31574VU1/ 
2018 
5. Ethosomes Liposomes and ethosomes charged with 
Rosmarinic acid suitable for use in cosmetics 
Karatoprak gokche, Yucel cigdem W02020117163A1/ 
2020 
Method of preparing bioactive substance 
encapsulated ethosome  




Active skin care composition and application Chen jianhuan, Chen songbin, Liu jiesen, Luo 





Lipid compositions containing bioactive fatty 
acids 
Berger Alvin, remmereit jan US10537542B2/ 
2020 
Preparation of multi-layer Transfersomes 
containing linoleic acid and alpha-linoleic 
acid ester complexes using organic acid 
hydrolysis and fatty acid esterification from 
flax seeds 
Yoo dong min KR102008266B1/ 
2019 
Aripiprazole compositions and methods for 
transdermal delivery 




7. Invasome Ibuprofen nanoparticle carriers encapsulated 
with hermetic surfactant films 
Morrison eric. US10561627B2/ 
2020 
Bacteria based protein delivery Arrieumeriou Cecile, lttig simon EP3145946B1/ 
2019 
Therapeutic agents for skin diseases and 
conditions 
Vander jagt david L, Deck Lorraine M, Royer 
Robert E, Heidrich john E 
US9925153B2/ 
2018 
8. Sphingosom Targeted therapeutics Jain neera, Ying weiwen, Chimmanamada WO2018236781A3/ 
Brito et al. 
Int J App Pharm, Vol 12, Issue 6, 2020, 7-18 
16 
e dinesh, Zhang junyi, Kale amit 2020 
Therapeutic elastic bandage for modulating 
the endocannabinoid system 
Erbst steven Robert, Erbst Cameron Patrick, 
Weber Mathew lee 
WO2019194871A1/ 
2019 
Elastomeric articles having skin care 
properties and methods for their production 
Foo khon pu, Lim chin keong AU2017279818A1/ 
2018 
 
Table 7: Report on various route of administration of Somes and its importance 
S. No. Type of 
Somes/Carrier 
Route of administration  Reason Reference 
1. Liposomes  Topical route of administration 
by using Triamcinolone as a 
model drug 
Liposomes alter the Triamcinolone arrangement and induce 
local rather than systemic effects. 
85 
2. Niosomes  Ocular delivery by using 
Cyclopentolate as drug 
As compared to other somes, niosomes are used as a 
successful carrier for cyclopentolates. 
86 
3. Aquasomes  Oral delivery of enzymes like 
Serratiopeptidase  
Serratiopeptidase acts against inflammation. The key reason 
for using aquasomes as carrier is because of its property of 
preserving the bioactive molecules' conformational integrity. 
It shows that aquasomes have the ability to bear the 
pharmaceutical related peptide. 
87 
4. Transfersomes  Non-invasive topical delivery of 
antigen(Tetanus toxoid)/topical 
immunization  
Transfersomes is a more efficient non-invasive topical 
delivery of tetanus toxoids compared to niosomes and 
liposomes that cause weaker immune responses. 
88 
5. Invasomes  Transdermal delivery of 
isradipine 
The prepared Isradipine loaded invasomes deliver 
ameliorated flux show better trap efficiency and transdermal 
delivery efficiency and reduced hypertension compared to the 
other somes carrier. 
89 
6. Phytosomes  Oral route of administration by 
using silymarin (flavonoid 
complex obtained from milk 
thistle) 
Silymarin is a heptoprotective agent resulting in decreased 
bioavailability due to its low solubility in both water and oil, 
and low intestinal permeability. To overcome this problem, 
phytosomes loaded with silymarin are produced to improve 
protection and stability in the bioavailability. 
90 
  
Table 8: Report on marketed products of various somes 
S. No. Type of somes Marketed product Active drug  Company and manufacturer 
1. Niosomes Lancome® Antiageing agent Loreal, Paris 
2. Liposomes DaunoXome® Daunorubicin Galen limited, United Kingdom 
DepoCyt® Cytarabine Pacira pharmaceuticals Inc. California, USA 
Mifamurtide® Mepact Takeda pharmaceuticals, Tokyo, Japan 
3. Ethosomes Decorin cream® Antiageing agent Genome cosmetics, USA 
Nanominox® Minoxidil Sincere, Germany 
Supravir cream® Acyclovir Triama, Isreal 
4. Phytosomes Sllybin phytosome® Sllybin from Sllbium 
marianum 
Thorne research Inc., New York 
Haw thorn 
phytosome® 
Vitexin Swason ultra, North Dokata 
Glinko select 
phytosome® 
Flavonoids from Glinko 
biloba 
Natural factors, Canada 
5. Sphingosomes Marqibo TM Vincristine Eli Lily, India 
Navelbine ® Vinorelbine Glaskosmithkline, England 
Hycumtin ® Topotecan Glaskomithkline, England 
 
CONCLUSION 
Nanosomes carrier are well known for their potential application. 
There are various types of nanosomes carrier available, for example 
liposomes, which act as a superior carrier since it as the capacity to 
encapsulate both hydrophilic and lipophilic drug to defend from 
degradation. The nanosomes can be manufactured by number of 
method which based upon the property of the drug molecule. The 
drug which is present in the nanosomes administrated by numerous 
routes which include intravenous, oral inhalation, transdermal for 
the treatment of various diseases and it is also helpful to surmount 
the certain drawbacks related with drug moiety such as stability, 
degradation, side effect and bioavailability by incorporating the drug 
into the nanosomes. 
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